Interesting Publications from Others

  1. Thiel P, Kaiser M, Ottmann C. Small-molecule stabilization of protein-protein interactions: an underestimated concept in drug discovery? (2012) Angew Chem.;51(9):2012-8. doi: 10.1002/anie.201107616.

  2. Buckley LD, Van Molle I, Gareiss PC, Tae HS, Michel J, Noblin DJ, Jorgensen WL, Ciulli A, Crews CM (2012) Targeting the von Hippel–Lindau E3 Ubiquitin Ligase Using Small Molecules To Disrupt the VHL/HIF-1? Interaction J. Am. Chem. Soc., DOI: 10.1021/ja209924v

  3. Surade S, Blundell TL, (2012)  Structural Biology and Drug Discovery of Difficult Targets: The Limits of Ligandability. Chemistry & Biology. Volume 19, Issue 1, Pages 42–50

  4. Wanner J, Fry DC, Peng Z, Roberts J. (2011) Druggability assessment of protein-protein interfaces. Future Med Chem. Dec;3(16):2021-38.

  5. Bullock BN, Jochim AL and Arora PS (2011) Assessing Helical Protein Interfaces for Inhibitor Design. J. Am. Chem. Soc. DOI: 10.1021/ja206074j

  6. Morelli X, Bourgeas R and Roche P (2011) Chemical and structural lessons from recent successes in protein-protein interaction inhibition (2P2I). Curr. Opin. Chem. Biol. 15:475-481

  7. Phillips C, Roberts LR, et al. (2011) Design and Structure of Stapled Peptides Binding to Estrogen Receptors. Journal of the American Chemical Society 133:9696-9699

  8. Patgiri A, Yadav KK, Arora PS and Bar-Sagi D (2011) An orthosteric inhibitor of the Ras-Sos interaction. Nat. Chem. Biol. 7:585-587

  9. Wells JA and McClendon CL (2007) Reaching for high-hanging fruit in drug discovery at protein-protein interfaces. Nature. 450:1001-1009

  10. Vassilev LT, Vu BT, Graves B, et al. (2004) In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science. 303:844-848